TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Using the Telephone to Improve Care in Childhood Asthma
Brief Summary: Asthma is the most common chronic disease of childhood and a major cause of morbidity in the United States. If asthma symptoms are controlled, a child with asthma can stay well and lead a normal life. Daily use of inhaled steroids controls symptoms and reduces morbidity and emergent health care utilization in children with persistent asthma, and is safe for long-term use. However, inhaled steroids are underused in community asthma care.

The Telephone Asthma Program (TAP) is a series of brief, telephone calls with a trained coach to help the parent manage the child's asthma care. The coach will teach self-management skills, help the parent to use the child's asthma medicines effectively, provide support and remind the parent to go for follow-up care with the pediatrician. We hypothesized that the Telephone Asthma Program will reduce the incidence of acute exacerbations of asthma that require emergent care, improve the quality of life of children with asthma and their parents, and increase the daily use of inhaled steroids in children with persistent asthma. We evaluated the Telephone Asthma Program in a randomized controlled trial involving 362 children aged 5 to 12 years old cared for by community pediatricians. Eligible children were randomized to the TAP program or usual care by their pediatrician.


Options:
A: Intervention Type: BEHAVIORAL; Name: Problem-Solving Skills Training; Assigned to Arm(s): N/A
B: Arm Label: Social learning and cognitive behavioral therapy (SLCBT); Type: EXPERIMENTAL; Interventions: Behavioral: Social Learning and Cognitive Behavioral Therapy (SLCBT) | Arm Label: Education Support (ES); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education Support (ES) | Intervention Type: BEHAVIORAL; Name: Social Learning and Cognitive Behavioral Therapy (SLCBT); Assigned to Arm(s): Social learning and cognitive behavioral therapy (SLCBT) | Intervention Type: BEHAVIORAL; Name: Education Support (ES); Assigned to Arm(s): Education Support (ES)
C: Arm Label: Coaching group for lifestyle changes; Type: EXPERIMENTAL; Interventions: Behavioral: Coaching | Arm Label: Routine pediatric care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Coaching; Assigned to Arm(s): Coaching group for lifestyle changes
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone Asthma Program | Intervention Type: BEHAVIORAL; Name: Telephone Asthma Program; Assigned to Arm(s): Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Placebo-controlled, Multi-centre, Phase III Study to Assess Efficacy and Safety of STALORAL® 300 IR Sublingual Immunotherapy (SLIT) in Chinese Asthmatic Patients Allergic to House-dust Mites
Brief Summary: A phase III study to assess the efficacy and safety of sublingual immunotherapy with STALORAL dust mites solution compared with placebo for reduction of asthma symptoms.


Options:
A: Intervention Type: DRUG; Name: ALK HDM tablet; Assigned to Arm(s): N/A
B: Arm Label: SLIT; Type: EXPERIMENTAL; Interventions: Biological: sublingual immunotherapy | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: sublingual immunotherapy; Assigned to Arm(s): SLIT | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Staloral | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Staloral | Intervention Type: DRUG; Name: Staloral; Assigned to Arm(s): 1, 2
D: Arm Label: 300 IR; Type: EXPERIMENTAL; Interventions: Drug: 300 IR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 300 IR; Assigned to Arm(s): 300 IR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Placebo-controlled, Multi-centre, Phase III Study to Assess Efficacy and Safety of STALORAL® 300 IR Sublingual Immunotherapy (SLIT) in Chinese Asthmatic Patients Allergic to House-dust Mites
Brief Summary: A phase III study to assess the efficacy and safety of sublingual immunotherapy with STALORAL dust mites solution compared with placebo for reduction of asthma symptoms.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Staloral | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Staloral | Intervention Type: DRUG; Name: Staloral; Assigned to Arm(s): 1, 2
B: Arm Label: MK-8237 6 DU; Type: EXPERIMENTAL; Interventions: Biological: MK-8237 6 DU | Arm Label: MK-8237 12 DU; Type: EXPERIMENTAL; Interventions: Biological: MK-8237 12 DU | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: MK-8237 6 DU; Assigned to Arm(s): MK-8237 6 DU | Intervention Type: BIOLOGICAL; Name: MK-8237 12 DU; Assigned to Arm(s): MK-8237 12 DU | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: BIOLOGICAL; Name: Recombinant birch pollen; Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: MK-8237 6 Developmental Units (DU); Type: EXPERIMENTAL; Interventions: Drug: MK-8237 6 DU | Arm Label: MK-8237 12 DU; Type: EXPERIMENTAL; Interventions: Drug: MK-8237 12 DU | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: MK-8237 6 DU; Assigned to Arm(s): MK-8237 6 Developmental Units (DU) | Intervention Type: DRUG; Name: MK-8237 12 DU; Assigned to Arm(s): MK-8237 12 DU

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimized Treatment Algorithm in Early Rheumatoid Arthritis: Methotrexate and Intra-articular Glucocorticosteroid Plus Adalimumab or Placebo in the Treatment of Early Rheumatoid Arthritis
Brief Summary: Optimized treatment algorithm in early rheumatoid arthritis:

Methotrexate and intra-articular glucocorticosteroid plus adalimumab or placebo in the treatment of early rheumatoid arthritis.

A Randomised, double-blind and placebo-controlled, two arms, parallel group study of the additive effect of adalimumab concerning inflammatory control and inhibition of erosive development.

Optimized Treatment Algorithms for Patients with Early RA


Options:
A: Arm Label: Abatacept (ABA) + Methotrexate (MTX) (double-blind [DB]); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB) | Arm Label: Infliximab + MTX (DB); Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab (INF) + MTX, DB | Arm Label: Placebo + MTX (DB); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (PLA) + MTX, DB | Arm Label: Placebo + MTX switched to abatacept + MTX (DB); Type: EXPERIMENTAL; Interventions: Drug: PLA + MTX switched to ABA+ MTX, DB | Arm Label: Abatacept (open-label); Type: EXPERIMENTAL; Interventions: Drug: ABA, open-label (OL) | Intervention Type: DRUG; Name: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB); Assigned to Arm(s): Abatacept (ABA) + Methotrexate (MTX) (double-blind [DB]) | Intervention Type: DRUG; Name: Infliximab (INF) + MTX, DB; Assigned to Arm(s): Infliximab + MTX (DB) | Intervention Type: DRUG; Name: Placebo (PLA) + MTX, DB; Assigned to Arm(s): Placebo + MTX (DB) | Intervention Type: DRUG; Name: PLA + MTX switched to ABA+ MTX, DB; Assigned to Arm(s): Placebo + MTX switched to abatacept + MTX (DB) | Intervention Type: DRUG; Name: ABA, open-label (OL); Assigned to Arm(s): Abatacept (open-label)
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept , Methotrexate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide | Intervention Type: DRUG; Name: Etanercept , Methotrexate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra] | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1
D: Arm Label: methotrexate + adalimumab; Type: EXPERIMENTAL; Interventions: Drug: Adalimumab | Arm Label: methotrexate + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): methotrexate + adalimumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): methotrexate + placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimized Treatment Algorithm in Early Rheumatoid Arthritis: Methotrexate and Intra-articular Glucocorticosteroid Plus Adalimumab or Placebo in the Treatment of Early Rheumatoid Arthritis
Brief Summary: Optimized treatment algorithm in early rheumatoid arthritis:

Methotrexate and intra-articular glucocorticosteroid plus adalimumab or placebo in the treatment of early rheumatoid arthritis.

A Randomised, double-blind and placebo-controlled, two arms, parallel group study of the additive effect of adalimumab concerning inflammatory control and inhibition of erosive development.

Optimized Treatment Algorithms for Patients with Early RA


Options:
A: Arm Label: Canakinumab 600 mg IV + 300 mg q2wk; Type: EXPERIMENTAL; Interventions: Drug: Canakinumab | Arm Label: Canakinumab 300 mg q2wk; Type: EXPERIMENTAL; Interventions: Drug: Canakinumab | Arm Label: Canakinumab 150 mg q4wk; Type: EXPERIMENTAL; Interventions: Drug: Canakinumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Canakinumab; Assigned to Arm(s): Canakinumab 150 mg q4wk, Canakinumab 300 mg q2wk, Canakinumab 600 mg IV + 300 mg q2wk | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: methotrexate + adalimumab; Type: EXPERIMENTAL; Interventions: Drug: Adalimumab | Arm Label: methotrexate + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): methotrexate + adalimumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): methotrexate + placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate, Drug: tocilizumab [RoActemra/Actemra] | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate, Drug: tocilizumab [RoActemra/Actemra] | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1
D: Arm Label: Group 1: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Biological: Golimumab 50 mg | Arm Label: Group 2: Golimumab 50 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 50 mg | Arm Label: Group 3: Golimumab 100 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1: Placebo | Intervention Type: BIOLOGICAL; Name: Golimumab 50 mg; Assigned to Arm(s): Group 1: Placebo, Group 2: Golimumab 50 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 100 mg; Assigned to Arm(s): Group 3: Golimumab 100 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimized Treatment Algorithm in Early Rheumatoid Arthritis: Methotrexate and Intra-articular Glucocorticosteroid Plus Adalimumab or Placebo in the Treatment of Early Rheumatoid Arthritis
Brief Summary: Optimized treatment algorithm in early rheumatoid arthritis:

Methotrexate and intra-articular glucocorticosteroid plus adalimumab or placebo in the treatment of early rheumatoid arthritis.

A Randomised, double-blind and placebo-controlled, two arms, parallel group study of the additive effect of adalimumab concerning inflammatory control and inhibition of erosive development.

Optimized Treatment Algorithms for Patients with Early RA


Options:
A: Arm Label: methotrexate + adalimumab; Type: EXPERIMENTAL; Interventions: Drug: Adalimumab | Arm Label: methotrexate + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): methotrexate + adalimumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): methotrexate + placebo
B: Arm Label: Open-Label Active Treatment Enrolled from Phase 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Open-Label Active Treatment Enrolled from Phase 3; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Open-Label Active Treatment Enrolled from Phase 2 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Open-Label Active Treatment Enrolled from Phase 3
C: Arm Label: Tocilizumab 8 mg/kg + DMARDs; Type: EXPERIMENTAL; Interventions: Drug: Tocilizumab, Drug: Permitted DMARDs | Arm Label: Placebo + DMARDs; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Permitted DMARDs | Intervention Type: DRUG; Name: Tocilizumab; Assigned to Arm(s): Tocilizumab 8 mg/kg + DMARDs | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + DMARDs | Intervention Type: DRUG; Name: Permitted DMARDs; Assigned to Arm(s): Placebo + DMARDs, Tocilizumab 8 mg/kg + DMARDs
D: Arm Label: Certolizumab pegol 200 mg (CDP870); Type: EXPERIMENTAL; Interventions: Biological: Certolizumab pegol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Certolizumab pegol; Assigned to Arm(s): Certolizumab pegol 200 mg (CDP870) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of OroPharyngeal Exercises on Patients With Moderate Obstructive Sleep Apnea: A Randomized, Controlled Study
Brief Summary: Background: Upper airway muscle weakness plays an important role in the genesis of obstructive sleep apnea (OSA). Oropharyngeal exercises are derived from speech therapy consisting of isometric and isotonic exercises directed to tongue, soft palate and lateral pharyngeal wall. We hypothesized that oropharyngeal exercises will attenuate OSA severity.

We will include 30 moderate OSA patients (apnea-hypopnea index (AHI), between 15 and 30 events/hour) that will randomize to 3 months of general measurements and daily nasal lavage (n=15, control) or daily oropharyngeal exercises (\~30 min) plus nasal lavage (n=16). Full polysomnography, anthropometric measurements, questionnaires derived from Berlin, Epworth and Pittsburgh evaluating quantitatively (range) snoring frequency (0-4) and intensity (1-3), daytime sleepiness (0-24) and sleep quality (0-21), respectively will be performed at baseline and study end.


Options:
A: Arm Label: 1; Type: SHAM_COMPARATOR; Interventions: Behavioral: Deep breathing, bilateral alternate chewing, nasal lavage | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Oropharyngeal exercises | Intervention Type: BEHAVIORAL; Name: Deep breathing, bilateral alternate chewing, nasal lavage; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Oropharyngeal exercises; Assigned to Arm(s): 2
B: Arm Label: placebo exercices; Type: PLACEBO_COMPARATOR; Interventions: Device: Continuous Positive Airway Pressure (CPAP) | Arm Label: phonoaudiologic therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Continuous Positive Airway Pressure (CPAP) | Intervention Type: DEVICE; Name: Continuous Positive Airway Pressure (CPAP); Assigned to Arm(s): phonoaudiologic therapy, placebo exercices
C: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Control | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Smart phone game play | Intervention Type: OTHER; Name: Smart phone game play; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Oropharyngeal exercises | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Behavioral: Respiratory exercises, nasal dilator, nasal lavage | Intervention Type: BEHAVIORAL; Name: Oropharyngeal exercises; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Respiratory exercises, nasal dilator, nasal lavage; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimizing Drug-Therapy in Patients, 80 Years and Older, in Order to Reduce Drug-Related Morbidity and Usage of Secondary Care - a Randomized Controlled Trial
Brief Summary: The purpose of this study is to measure the effects of an enhanced service where a pharmacists is part of the healthcare team on the ward (focusing on drug-related problems and transferring information between primary and secondary care). Primary outcome measure is visits to hospital during a 12-month follow-up period, and the population is patients 80 years and older.


Options:
A: Arm Label: SENATOR; Type: EXPERIMENTAL; Interventions: Other: SENATOR software generated pharmacotherapy advice report. | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: SENATOR software generated pharmacotherapy advice report.; Assigned to Arm(s): SENATOR
B: Intervention Type: BEHAVIORAL; Name: Integration of a team based clinical pharmacist; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Optimizing therapeutic treatments; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Optimizing processes of care; Assigned to Arm(s): N/A
C: Arm Label: I; Type: EXPERIMENTAL; Interventions: Other: Drug review 80+ -To reduce usage of hospital care | Arm Label: C; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Drug review 80+ -To reduce usage of hospital care; Assigned to Arm(s): I
D: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Pharmacist obtains home med hx; Type: EXPERIMENTAL; Interventions: Other: Pharmacist obtains admission medication history | Arm Label: Pharm tech obtains home med hx; Type: EXPERIMENTAL; Interventions: Other: Pharmacy technician obtains admission medication history | Intervention Type: OTHER; Name: Pharmacist obtains admission medication history; Assigned to Arm(s): Pharmacist obtains home med hx | Intervention Type: OTHER; Name: Pharmacy technician obtains admission medication history; Assigned to Arm(s): Pharm tech obtains home med hx

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimizing Drug-Therapy in Patients, 80 Years and Older, in Order to Reduce Drug-Related Morbidity and Usage of Secondary Care - a Randomized Controlled Trial
Brief Summary: The purpose of this study is to measure the effects of an enhanced service where a pharmacists is part of the healthcare team on the ward (focusing on drug-related problems and transferring information between primary and secondary care). Primary outcome measure is visits to hospital during a 12-month follow-up period, and the population is patients 80 years and older.


Options:
A: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Pharmacist obtains home med hx; Type: EXPERIMENTAL; Interventions: Other: Pharmacist obtains admission medication history | Arm Label: Pharm tech obtains home med hx; Type: EXPERIMENTAL; Interventions: Other: Pharmacy technician obtains admission medication history | Intervention Type: OTHER; Name: Pharmacist obtains admission medication history; Assigned to Arm(s): Pharmacist obtains home med hx | Intervention Type: OTHER; Name: Pharmacy technician obtains admission medication history; Assigned to Arm(s): Pharm tech obtains home med hx
B: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Procedure: New technology - PAML | Intervention Type: PROCEDURE; Name: New technology - PAML; Assigned to Arm(s): Intervention
C: Arm Label: I; Type: EXPERIMENTAL; Interventions: Other: Drug review 80+ -To reduce usage of hospital care | Arm Label: C; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Drug review 80+ -To reduce usage of hospital care; Assigned to Arm(s): I
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Pharmacist Intervention for Low-Literacy in Cardiovascular Disease | Intervention Type: BEHAVIORAL; Name: Pharmacist Intervention for Low-Literacy in Cardiovascular Disease; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimizing Drug-Therapy in Patients, 80 Years and Older, in Order to Reduce Drug-Related Morbidity and Usage of Secondary Care - a Randomized Controlled Trial
Brief Summary: The purpose of this study is to measure the effects of an enhanced service where a pharmacists is part of the healthcare team on the ward (focusing on drug-related problems and transferring information between primary and secondary care). Primary outcome measure is visits to hospital during a 12-month follow-up period, and the population is patients 80 years and older.


Options:
A: Intervention Type: BEHAVIORAL; Name: Observation (behavior); Assigned to Arm(s): N/A
B: Arm Label: I; Type: EXPERIMENTAL; Interventions: Other: Drug review 80+ -To reduce usage of hospital care | Arm Label: C; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Drug review 80+ -To reduce usage of hospital care; Assigned to Arm(s): I
C: Arm Label: Pharmacist service,; Type: ACTIVE_COMPARATOR; Interventions: Other: Pharmacist service | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Pharmacist service; Assigned to Arm(s): Pharmacist service,
D: Arm Label: Minimal intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Minimal intervention | Arm Label: Enhanced intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Minimal intervention; Assigned to Arm(s): Minimal intervention | Intervention Type: BEHAVIORAL; Name: Enhanced Intervention; Assigned to Arm(s): Enhanced intervention

Answer: B